Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|10|2513-2519

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.10, 2015-11, pp. : 2513-2519

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Circulating Tumor Cell Data: Integration with Imaging and Serum Tumor Markers for Metastatic Breast Cancer Patient Management

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-03 ,pp. : 175-181

Karger

Access to resources Recommend Favorite

Serial profiling of circulating tumor DNA for optimization of anti‐VEGF chemotherapy in metastatic colorectal cancer patients

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 7, 2018-04 ,pp. : 1418-1426

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer

By  

GENES, CHROMOSOMES AND CANCER, Vol. 57, Iss. 4, 2018-04 ,pp. : 211-220

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP‐1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 6, 2015-05 ,pp. : 616-627

John Wiley & Sons Inc

Access to resources Recommend Favorite

Managing aromatase inhibitor-associated bone loss in breast cancer

By Lipton Allan   Gnant Michael   Aapro Matti  

Women's Health, Vol. 3, Iss. 4, 2007-07 ,pp. : 441-448

Future Medicine

Access to resources Recommend Favorite